external-file_edited (1)_edited_edited_edited_edited.png

Hello.

Welcome to BioFocus.
Explore the latest updates from the life science industry.

PHARMA

Innovent Biologics and Pfizer Forge $10.5 Billion Oncology Partnership

Strategic collaboration combines Innovent’s early-stage oncology innovation platform with Pfizer’s global development and commercial capabilities across 12 cancer programs.

Featured Articles.

PHARMA

How Automation is Accelerating Drug Discovery Timelines

PHARMA

AI in Science Writing and the Imitation of Understanding

PHARMA

Pharma Smart Manufacturing 2026

HEALTH

The Risk AI Poses to Public Health

BIOTECH

Basecamp Research Launches the Trillion Gene Atlas

PHARMA

Inside Nxera Pharma’s Next-Generation Biopharma Model

HEALTH

A New Device Could Improve How Progesterone is Delivered in Early Pregnancy

BIOTECH

UK Biotech Cyclana Bio is Trying to Understand Endometriosis From the Tissue Up and it's Just Recruited its First Patients

BIOTECH

PRISM ALS Sets Out to Improve ALS/MND Drug Discovery

Latest News.

14th June, 2026

02. Laverock Therapeutics Advances CAR-T and Macrophage Programmes with Solid Tumour Data

In-vivo results from both oncology programmes support lead candidate selection, as the UK biotech charts a path toward clinical trials.

3rd June, 2026

03. Pharma Smart Manufacturing 2026

Europe's premier pharma conference on AI-enabled, GMP-compliant pharmaceutical manufacturing returns to Copenhagen.

29th May, 2026

04. Innovent Biologics and Pfizer Forge $10.5 Billion Oncology Partnership

Strategic collaboration combines Innovent’s early-stage oncology innovation platform with Pfizer’s global development and commercial capabilities across 12 cancer programs.

25th June, 2026

01. FairJourney Bio Expands End-to-End Antibody Discovery Through New AbTherx Partnership

FairJourney Bio has announced a strategic partnership with AbTherx to bring transgenic mouse-based antibody discovery capabilities in-house, creating a fully integrated antibody discovery workflow designed to accelerate therapeutic development.